Signal Genetics Files for $25M IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Signal Genetics plans to offer 2,272,000 shares of common stock at $10 to $12 per share through its initial public offering, the cancer molecular diagnostics company said in a prospectus filing with the US Securities and Exchange Commission.

Assuming an average price of $11 per share, the company expects to raise about $25 million through the offering, if the underwrites exercise their full over-allotment option for an additional 340,800 shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.